Abstract:
1. Abstract
Since the skin is the part of the human body that encounters the world most directly, it is particularly vulnerable to injury. When injuries take place, the skin will lose its function and its integrity, which may result in a life-threatening situation. Wounds may occur due to various causes that affect the wound healing normal physiological process which consists of four main stages: homeostasis, inflammation, proliferation and tissue remodelling. However; patients with diabetes mellitus (DM) suffer from wound healing impairment. DM has many drawbacks which influence the four stages of the healing process causing a delay in the healing, or proceeding to chronic wounds. Moreover, wounds may get infected due to bacterial colonization; thus antibiotics are used to defend the body against the bacterial infections such as tetracycline. Diabetic rat models with excisional wounding inoculated with staphylococcus aureus bacteria are used in the experiment, divided into 3 groups: control, standard tetracycline (suspension) and Sobulous patch containing tetracycline groups. Rats are then sacrificed to be tested physiologically and histologically in order to determine the difference between pharmacological effects of the market available tetracycline and the novel dosage form in the healing process and its effect on the collagen regeneration. The biochemical markers TNF-α, IL-1B, IL-10 are measured using ELIZA, while the MMP-9 is measured through PCR. The results are promising as the tetracycline decreases the pro-inflammatory mediators and improve the anti-inflammatory mediators resulting in improved re-epithelization, granulation tissue formation, and accelerated wound closure. The aim of the study is to establish a wound healing model with a novel dosage form to increase the available market options for the targeted patients.
